TICKERNERD
Menu
GALTGALTHealthcare · Biotechnology

GALT Stock Forecast: Galectin Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$3.84
−1.79% on the day

The 1 Wall Street analysts covering Galectin Therapeutics, Inc. hold a median 12-month price target of $11 — +186.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 12 Sept 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$394.3M
Ticker Nerd rank
70 / 100
Median analyst target
$11
Analysts covering
1
Revenue$0.0
Operating income−$4.0M
Net income−$9.1M
Free cash flow−$2.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−16.7%
1M
+11.6%
YTD
−7.7%
1Y
−28.5%
From 52W high
−41.0%
From 52W low
+84.6%
$2.08
$6.51
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GALT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Galectin Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
70 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
90
Revisions
80
Value
80
Volatility
71
Growth
69
Size
57
Momentum
50
Quality
21
Issuance
13

Accruals (90): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (13): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GALT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GALT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26GALTHigh $11Median $11Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $11Median $11High $11

The green dot is the last close — the median target sits +186.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 June 2026HC Wainwright & Co.ReiteratesBuy$11
17 Dec 2025HC Wainwright & Co.MaintainsBuy—
14 Aug 2025HC Wainwright & Co.ReiteratesBuy—
17 June 2025HC Wainwright & Co.AssumesBuy$6.00
2 Apr 2025HC Wainwright & Co.ReiteratesNeutral—
27 Dec 2024HC Wainwright & Co.DowngradeNeutral—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
16 Aug 2024HC Wainwright & Co.ReiteratesBuy—
9 Apr 2024HC Wainwright & Co.ReiteratesBuy—
1 Apr 2024HC Wainwright & Co.ReiteratesBuy—
15 Aug 2023HC Wainwright & Co.ReiteratesBuy—
17 May 2023HC Wainwright & Co.ReiteratesBuy—
3 Mar 2023HC Wainwright & Co.ReiteratesBuy—
17 May 2022HC Wainwright & Co.MaintainsBuy—
16 Apr 2021HC Wainwright & Co.MaintainsBuy—
13 Aug 2020HC Wainwright & Co.MaintainsBuy—
3 Apr 2020B. Riley FBRMaintainsBuy—
3 Apr 2020B. Riley SecuritiesMaintainsBuy—
17 Mar 2020HC Wainwright & Co.MaintainsBuy—
13 Feb 2019B. Riley FBRInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GALT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

GALT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, Galectin Therapeutics, Inc. returned −28.5% against +17.5% for the S&P 500, dividends included.

GALT vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Oct 25Jan 26Apr 26Jul 26GALTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GALT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Galectin Therapeutics, Inc. (GALT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−8.2×

Cheaper than 92% of US stocks

Price / sales
—
Price / book
−1.9×

Cheaper than 95% of US stocks

EV / EBITDA
−26.5×

Cheaper than 91% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
24.5%

Higher than 85% of US stocks

Return on assets
−64.2%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Galectin Therapeutics, Inc. (GALT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Galectin Therapeutics, Inc. has a market value of $394.3M and an enterprise value of $527.2M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$27.8M.

  • Free cash flow in the twelve months to 30 June 2026: −$15.9M.

  • Shares outstanding: 66.3M.

  • Trailing P/E: −8.2×; forward P/E: −2.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Galectin Therapeutics, Inc. employs 9 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

GALT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GALTGalectin Therapeutics, Inc.$394.3M
70
BBOTBridgebio Oncology Therapeutics, Inc.$396.9M
9
RZLTRezolute, Inc.$403.8M
33
EVMNEvommune, Inc.$379.6M
10
BNTCBenitec Biopharma, Inc.$410.3M
42
LRMRLarimar Therapeutics, Inc.$413.9M
30
EDITEditas Medicine, Inc.$414.3M
78

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Galectin Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GALT news & analysis

Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 10 Sept 2026neutral

Galectin Therapeutics announced that company management will present and attend the H.C. Wainwright 28th Annual Global Investment Conference on September 10, 2026, as reported by GlobeNewsWire. The company, based in Norcross, Georgia, is a developer of therapeutics targeting galectin proteins.

Why it matters — The conference presentation gives GALT an opportunity to raise its profile with investors, though the announcement itself confirms no new developments.

20 stocks likely to lose money even if the bull market continues

Market Watch · 27 Aug 2026negative

Market Watch reports on a list of 20 stocks that are considered poor bets and likely to lose ground even if the broader bull market continues. The item states that certain stocks are such weak investments that they may decline despite overall market gains.

Why it matters — GALT watchers would care because such a list may flag certain stocks as vulnerable to losses even in a rising market, potentially affecting sentiment on the company.

Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update

GlobeNewsWire · 14 Aug 2026neutral

Galectin Therapeutics, Inc. reported its financial results and provided a business update for the three months ended June 30, 2026. The announcement was made via GlobeNewsWire on August 14, 2026, from the company's headquarters in Norcross, Georgia.

Why it matters — A GALT watcher would care because the quarterly financial results and business update offer insight into the company's recent performance and operational progress as a developer of therapeutics targeting galectin proteins.

Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet

GlobeNewsWire · 4 Aug 2026positive

Galectin Therapeutics announced that Chairman Richard E. Uihlein converted outstanding notes under five line of credit facilities into common stock, eliminating approximately $105.8 million in debt and increasing the company's market capitalization.

Why it matters — The debt-to-equity conversion removes roughly $105.8 million in liabilities, materially strengthening Galectin Therapeutics' balance sheet.

FAQ

Frequently asked questions about GALT stock

What is the GALT stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Galectin Therapeutics, Inc. have a median 12-month price target of $11, with estimates ranging from $11 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GALT stock a buy right now?

Of the 1 analysts covering Galectin Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Galectin Therapeutics, Inc. 70 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GALT?

As at 12 Sept 2026, Galectin Therapeutics, Inc. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (90 of 100).

Will GALT stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +186.5% from the last close, and Ticker Nerd's factor model ranks Galectin Therapeutics, Inc. 70 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GALT stock forecast for 2030?

No analyst covering Galectin Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GALT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $11 over the next 12 months.

How has GALT stock performed over the past year?

Galectin Therapeutics, Inc. returned -28.5% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Galectin Therapeutics, Inc. do?

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for fibrotic disease, cancer, and selected other chronic conditions.

What is the latest news on GALT?

The most recent item we track (GlobeNewsWire, 10 Sept 2026): "Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference". Galectin Therapeutics announced that company management will present and attend the H.C. Wainwright 28th Annual Global Investment Conference on September 10, 2026, as reported by GlobeNewsWire. The company, based in Norcross, Georgia, is a developer of therapeutics targeting galectin proteins.

Company

About Galectin Therapeutics, Inc.

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for fibrotic disease, cancer, and selected other chronic conditions. Galectin Therapeutics uses a carbohydrate-based approach centered on galectin science, targeting galectin proteins that play key roles in inflammation, fibrosis, and malignancy. Its lead product candidate, belapectin, is a galectin-3 inhibitor being studied in programs related to metabolic dysfunction-associated steatohepatitis, liver fibrosis, cirrhosis, and portal hypertension. The company also supports research into additional galectin-related treatments, including oral small-molecule inhibitors through collaborative efforts. Galectin Therapeutics is based in Norcross, Georgia, and operates within the biotechnology sector, where it focuses on discovery and development rather than commercial-scale product sales.

CEO Mr. Joel Lewis CPA · 9 employees · United States · https://galectintherapeutics.com